By killing a certain proportion of actively dividing CAR-T cells, the secretion of inflammatory cytokines by chimeric ... hence reducing production of IL-6, while retaining the efficacy of unaffected ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO ...

Researchers in China found multiple types of microplastics in human semen and urine, with exposure to PTFE significantly ...

COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA4-Ig fusion protein and is being ... simultaneously lowers the expression of activated microglia and the secretion of ...

FDA approved blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in ...

Eleven researchers across multiple disciplines of health science research have been awarded funding in the Health Research ...

Secretion of cytokines ... in cell membranes by 2.5 times. CONCLUSION In vitro OM-85 BV exerts immunomodulatory action via modulation of the signal transducer gp130 and gp130 binding cytokines. The ...

Horsetail mixture on rheumatoid arthritis and its regulation on TNF-α and IL-10. Pakistan Journal of Pharmaceutical ... of fasting glucose levels and insulin secretion in persons at high risk of ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Most persons with type 2 diabetes have lost 80% of their ability to secrete insulin by the time that symptoms emerge, and the impairment in insulin secretion progresses over time. 1 Standards of ...